| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate |
2007-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009542611-A |
| titleOfInvention |
Inhibition of alpha-synuclein aggregation |
| abstract |
The present invention relates to the inhibition of α-synuclein aggregation using peptidyl compounds and relates to retro-enantiomers of the peptidyl compound α-synuclein sequence, in particular sequences within the region between 1 to 60 residues or 61 to 96 residues. Retro enantiomer. The peptidyl compound of the present invention may be linked to a dopaminergic targeting moiety and / or a blood-brain barrier transport moiety as necessary in the treatment of α-synucleinopathies such as Parkinson's disease. Can be useful. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011116724-A |
| priorityDate |
2006-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |